Therapy Areas: Devices
ExThera Medical's Seraph 100 expected to reduce ICU length of stay and mortality rate in critically Ill COVID patients
1 September 2021 -

Blood filtration company ExThera Medical Corporation announced on Tuesday that physicians are using its Seraph 100 Microbind Affinity Blood Filter (Seraph 100) under the US Food and Drug Administration's emergency use authorisation to treat critically ill COVID patients.

Under the first multicentre randomized controlled trial of the Seraph 100, the company said it successfully treated hundreds of COVID patients and will be studying the treatment's ability to reduce ICU length of stay, hospital duration and mortality in patients suffering from septic shock.

With scheduled enrollment this Fall, the study will evaluate the safety and efficacy of pathogen-removing extracorporeal blood purification therapy in critically ill patients with pathogen-associated shock utilizing the company's Seraph 100 filter. The study will serve as the investigational device exemption (IDE) research needed for Seraph 100's FDA clearance.

This trial is sponsored by the Henry M. Jackson Foundation for the Advancement of Military Medicine in collaboration with the Uniformed Services University (USU) of the Health Sciences.

Login
Username:

Password: